Siegfried Announces Resolution of Hameln Pharma Regulatory Issues
The company announces that FDA has closed out a 2012 warning letter.
Siegfried announced on Feb. 16, 2015 that a 2012 FDA warning letter issued to Hameln Pharma has been resolved. Siegfried acquired the Hameln, Germany facility in November 2014.
FDA states in their close out letter dated Feb. 11, 2015 that the company successfully performed corrective and preventive actions and that the violations contained in the 2012 warning letter have been addressed. According to Siegfried, the resolution of the warning letter allows for the full integration of Hameln Pharma into the Siegfried Group, and American customers are now able to import products from the Hameln facility to the US.
“This is an announcement which our American customers, especially, have been waiting for. Revocation of the warning letter is the result of joint efforts. It represents a significant step in Hameln’s ongoing integration process into the Siegfried Group,” said Siegfried CEO Rudolf Hanko, in a press release.
Source: Siegfried Group
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
